Mutagenesis, Vol. 14, No. 3, 323-326,
May 1999
© 1999 UK Environmental Mutagen Society/Oxford University Press
Alternatives in the induction and preparation of phenobarbital/naphthoflavone-induced S9 and their activation profiles
Instituto de Farmacología y Toxicología Roemmers, Pavón 2885, 1248 Buenos Aires, Argentina
With the aim of optimizing the efficiency of S9 fractions used in in vitro mutagenicity assays, different schemes for the induction of liver enzymes in rats were tried and the amount of S9 fraction required was assessed. The activity of 2-anthramine (2AA), 2-acetylaminofluorene (2AAF), 3-methylcholanthrene (3MTCL) and benzo[a]pyrene in bacterial mutagenicity tests was compared with the enzymatic activity in S9 fractions obtained from rats treated with either phenobarbital (NaPB), ß-naphthoflavone (ßNF) or combinations of both. Three pool systems prepared with different amounts of NaPB-induced S9 and ßNF-induced S9 were also analyzed for their activation capacities. Profiles of standard plate incorporation assays with Salmonella typhimurium TA98 increased with the amount of S9 fraction added for all drugs tested, except for 2AA, which showed a maximun of activity at low protein concentrations. According to these profiles, an optimal S9 protein content of 700–1000 µg/plate was estimated. For 2AAF and 3MTCL an S9 fraction obtained following a simultaneous treatment with NaPB (i.p.) and ßNF (oral gavage) (NaPB+ßNF) yielded the greatest response. This preparation was the only one which produced positive activation with 3MTCL as test drug. With the other test drugs all the S9 fractions were very active, including the NAPB+ßNF-induced S9. Both Phase I and Phase II cytochrome P450 enzymatic activities were enhanced in this S9 fraction. These results suggest that the simultaneous treatment (NaPB+ßNF) would be an adequate inducer for in vitro activation when used at 700–1000 µg protein/plate.
1 To whom correspondence should be addressed. Tel/Fax: +54 11 4308 0501; Email: sgarc\|[iacute]\|a{at}roemmers.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Hakura, H. Shimada, M. Nakajima, H. Sui, S. Kitamoto, S. Suzuki, and T. Satoh Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds Mutagenesis, May 1, 2005; 20(3): 217 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jemnitz, Z. Veres, G. Torok, E. Toth, and L. Vereczkey Comparative study in the Ames test of benzo[a]pyrene and 2-aminoanthracene metabolic activation using rat hepatic S9 and hepatocytes following in vivo or in vitro induction Mutagenesis, May 1, 2004; 19(3): 245 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mori, A. Koide, K. Fuwa, and Y. Kobayashi N-Benzylimidazole for preparation of S9 fraction with multi-induction of metabolizing enzymes in short-term genotoxicity assays Mutagenesis, November 1, 2001; 16(6): 479 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Escobar-Garcia, R. Camacho-Carranza, I. Perez, V. Dorado, M. Arriaga-Alba, and J.J. Espinosa-Aguirre S9 induction by the combined treatment with cyclohexanol and albendazole Mutagenesis, November 1, 2001; 16(6): 523 - 528. [Abstract] [Full Text] [PDF]
|
|